Charles River Laboratories International, Inc.’s Stock Price Skyrockets to $201.75, Marking a Robust 5.18% Uptick

Charles River Laboratories International, Inc. (CRL)

201.75 USD +9.94 (+5.18%) Volume: 0.63M

Charles River Laboratories International, Inc.’s stock price stands at 201.75 USD, witnessing a positive surge of +5.18% this trading session with a trading volume of 0.63M, despite a YTD decrease of -15.04%, indicating a dynamic performance in the market.

Latest developments on Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. (NYSE:CRL) has seen fluctuations in its stock price today following a series of key events. Quantinno Capital Management LP recently increased their holdings in the company, while Quadrature Capital Ltd trimmed their stake. Additionally, Janus Henderson Group PLC purchased more shares of Charles River Laboratories, and iA Global Asset Management Inc. also boosted their position. These movements come amidst the company’s ongoing efforts in phenotyping a TDP-43 model for ALS drug discovery and characterizing the mouse spared nerve injury model, showcasing their commitment to advancing research and development in the healthcare industry.

A look at Charles River Laboratories International, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

According to Smartkarma Smart Scores, Charles River Laboratories has a mixed long-term outlook. The company scores well in terms of growth and momentum, indicating potential for future expansion and positive market performance. However, its scores for value, resilience, and dividend are lower, suggesting some weaknesses in these areas that investors may need to consider. Charles River Laboratories provides research tools and support services for drug discovery and development, catering to a wide range of customers in the pharmaceutical and biotechnology industries, as well as hospitals and academic institutions.

Despite its lower scores in certain areas, Charles River Laboratories remains a key player in the research and development sector, providing essential animal research models for the creation of new drugs, devices, and therapies. With a focus on innovation and market momentum, the company is well-positioned to capitalize on opportunities for growth in the future. Investors should carefully weigh the different aspects of the Smartkarma Smart Scores to make informed decisions about the long-term prospects of Charles River Laboratories.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma